Feeds:
Posts
Comments

Posts Tagged ‘prostate cancer growth’

URO TODAY: Activation of the androgen receptor is crucial for prostate cancer growth at all points of the illness, and two new drugs are showing promise in preventing that happen. READ MORE>

Notably, promising activity has been shown in early phase trials by MDV3100, a new anti-androgen designed for activity in prostate cancer model systems with over-expressed androgen receptor, and by abiraterone acetate, a CYP17A inhibitor that blocks steroid biosynthesis in the adrenal gland and possibly within the tumour. Both agents are undergoing phase three testing.

Read Full Post »

NZ HERALD: Otago University biomedical researchers have been awarded a $950,000 Health Research Council Grant for a three-year project to investigate the likely role of a protein, activin C, in promoting prostate cancer growth. READ MORE>

Read Full Post »